Markets News
Latest stock market news and real-time market analysis. Track S&P 500, Nasdaq, and Dow Jones movements, sector rotations, and breaking market events.
London Stocks Dip as BT Stalls, Sage Shines, and Oil Jitters Return
The FTSE 100 fell 0.34% on Thursday as BT's flat core earnings, easyJet's loss warning, and oil above $106 weighed on the index, though Sage's raised outlook provided a bright spot.
Indian Stocks Hold Gains on Lower Oil, Rupee Recovery
Indian stocks traded higher on Thursday, supported by a drop in oil prices and a rebound in the rupee after RBI intervention, with Apollo Hospitals and Lenskart gaining on strong earnings.
Silexion Rockets 97% on Cancer Trial News, Nasdaq Compliance and Cash Concerns Remain
Silexion Therapeutics shares surged 97% on Wednesday following Israeli approval for a Phase 2/3 trial of its pancreatic cancer drug SIL204, but the company still grapples with cash burn, dilution risks, and Nasdaq compliance.
Jupiter Neurosciences Shares Plunge on $100M MDMA Deal and Dilutive Offering
Jupiter Neurosciences shares fell 37% to $0.205 after announcing a $100M licensing deal for MDMA drug ALA-002 and a $2M stock offering, with trading volume exceeding 230 million shares.
Immunovant Shares Surge on Promising Arthritis Drug Data
Immunovant shares soared 35% after its experimental rheumatoid arthritis drug, IMVT-1402, demonstrated high response rates in a difficult-to-treat patient population, prompting a re-rating by Wall Street.
FuelCell Energy Stock Jumps 16.5% on Renewed AI Data Center Optimism, Analysts Remain Cautious
FuelCell Energy shares surged 16.5% to $20.22 on renewed AI data center demand, but analysts remain cautious as the company reported a $26.1M loss and declining backlog.
RBC Shares Hit Fresh 52-Week High Ahead of Q2 Earnings Report
RBC shares hit a 52-week high of C$257.91 on Wednesday, rising 1.99% to C$257.55, ahead of its Q2 earnings release on May 28.
HCW Biologics Rockets 122% as Traders Flock to Micro-Cap Biotech
HCW Biologics shares skyrocketed 122% to $2.35 on Wednesday as traders piled into the micro-cap biotech, fueled by a new stock offering and first-quarter revenue of $6.54 million from a licensing deal.
